AXSM Axsome Therapeutics, Inc.
Healthcare$234.20-0.75%ClosedMarket Cap: $12.05B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
221.32
P/S
17.15
EV/EBITDA
-69.79
DCF Value
$-470.32
FCF Yield
-0.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.6%
Operating Margin
-24.8%
Net Margin
-26.6%
ROE
-260.0%
ROA
-26.4%
ROIC
-50.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $191.2M | 92.3% | $-63.4M | $-64.5M | $— | — |
| Q4 null | $196.0M | 93.7% | $-29.4M | $-28.6M | $— | — |
| FY null | $638.5M | 92.6% | $-169.2M | $-183.2M | $— | — |
| Q3 null | $171.0M | 93.0% | $-46.1M | $-47.2M | $— | — |
| Q2 null | $150.0M | 91.0% | $-36.7M | $-48.0M | $— | — |
| Q1 null | $121.5M | 91.9% | $-57.0M | $-59.4M | $— | — |
| Q4 null | $118.8M | 91.1% | $-72.6M | $-74.9M | $— | — |
| FY null | $385.7M | 91.4% | $-280.6M | $-287.2M | $— | — |
| Q3 null | $104.8M | 91.9% | $-62.6M | $-64.6M | $— | — |
| Q2 null | $87.2M | 90.8% | $-78.0M | $-79.3M | $— | — |
| Q1 null | $75.0M | 91.6% | $-67.3M | $-68.4M | $— | — |
| Q4 2023 | $71.5M | 89.7% | $-98.3M | $-98.7M | $-2.08 | — |